Keros Therapeutics Q2 net loss narrows on lower expenses

Keros Therapeutics

03/08/2026 21:11

Overview
US biopharma firm's Q2 net loss narrowed yr/yr due to lower R&D and admin expenses
Company began Phase 2 trial of rinvatercept in Duchenne muscular dystrophy
Cash and equivalents at end-Q2 stood at $257.6 mln; runway into H1 2028 expected

Outlook
Keros expects cash and cash equivalents to fund operations into the first half of 2028
Company expects initial data from Phase 2 rinvatercept trial in DMD in first half of 2027

Result Drivers
R&D SPEND DROP - Research and development expenses fell sharply due to transition of elritercept-related R&D to Takeda and corporate restructuring
LOWER ADMIN COSTS - General and administrative expenses declined due to reduced professional fees and compensation costs following 2025 restructuring

Company press release: ID:nGNXcdLWvy

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$28.71 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Keros Therapeutics Inc is $20.00, about 98.6% above its July 31 closing price of $10.07

Reuters Recommended Reads
Aug 3 - Design Therapeutics Q2 net loss narrower than expected
Aug 3 - TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales
Aug 3 - Supernus, Indivior merge to strengthen neuroscience drug portfolio

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)